|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation.
|
14522889 |
2003 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi.
|
12447372 |
2003 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of B-raf exon 15 mutations or prediction of the activating mutation V599E were not statistically associated with the risk for subsequent metastasis in the follow-up of patients.
|
15331929 |
2004 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sixty-eight samples (20 of 36 primaries, 18 of 27 regional metastases, 16 of 40 nodal metastases, and 9 of 12 distant metastases) harbored the V599E B-RAF mutation (59%), 17 contained a Q61R N-RAS mutation, and 4 contained a Q61K N-RAS mutation.
|
15737846 |
2005 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unexpectedly, V599 and V599E mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as preceding primary tumours.
|
15935100 |
2005 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF V599E mutations.
|
16098043 |
2005 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) significantly correlated with absence of node metastasis.
|
16452550 |
2006 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, this study provides a mechanistic basis for targeting Mek and not B-Raf in the mutant (V600E)B-Raf signaling cascade to inhibit melanoma metastases.
|
16912199 |
2006 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Together, these results suggest that targeting mutant (V600E)B-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-beta2 integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant (V600E)B-Raf to inhibit melanoma extravasation and subsequent metastasis development.
|
17575149 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in 88 of the tumors examined, with significant differences between groups with and without lymph node (LN) metastases; the mean age of patients with BRAF(V600E) mutation was significantly higher than that of patients without mutations.
|
17685465 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation is identified in a subset of cutaneous metastases from PTC.
|
17387744 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001).
|
18310287 |
2008 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior.
|
19034577 |
2009 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The activating mutation BRAF(V600E) is a frequent genetic event in papillary thyroid carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radioiodide-refractory metastatic disease.
|
19861538 |
2009 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK.
|
20605766 |
2010 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis.
|
21447745 |
2011 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their metastases, and BRAF(V600E) is associated with poorer outcomes in metastatic patients.
|
20635392 |
2011 |
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery.
|
21948220 |
2011 |